AstraZeneca PLC (LON:AZN): The Best Of Both Worlds
Attractive stocks have exceptional fundamentals. In the case of AstraZeneca PLC (LON:AZN), there’s is a company with a an impressive history of dividend payments as well as a excellent future outlook. Below, I’ve touched on some key aspects you should know on a high level. For those interested in digger a bit deeper into my commentary, read the full report on AstraZeneca here.
High growth potential average dividend payer
AZN is an attractive stock for growth-seeking investors, with an expected earnings growth of 25% in the upcoming year underlying the notable 41% return on equity over the next few years leading up to 2021.
AZN pays a decent dividend yield to its shareholders, higher than the low-risk savings rate, which is what investors want in order to compensate them for the risk of holding a stock.
Next Steps:
For AstraZeneca, I’ve put together three pertinent factors you should further research:
Historical Performance: What has AZN’s returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
Valuation: What is AZN worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether AZN is currently mispriced by the market.
Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of AZN? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!
To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.
